Barrett’s Esophagus: Emerging Knowledge and Management Strategies

Table 2

Incidence of neoplastic progression of low-grade dysplasia*.

Study (reference)	Number of BE patients followed	Duration of followup	Incidence of EAC/HGD
Bhat et al. [7]	8522 with BE, (no IM required)	7 years (mean)	1.4% per year (EAC)
Hvid-Jensen et al. [14]	11,028 with BE	5.2 years (median)	0.5% per year (EAC)
Sharma et al. [43]	618 with BE; LGD diagnosed in 156 during f/u	2546 patient years (mean 4.12 years)	0.6% per year (EAC)
Lim et al. [44]	357 with BE; LGD diagnosed in 34 during f/u	8 years	9/34 cases of HGD/EAC; 3.3% per year
Schouten et al. [45]	12,0852 with BE	5.7 years (median)	0.41% per year (EAC)
Curvers et al. [46]	147 LGD patients, but only 15% of these had a consensus diagnosis of LGD	51.1 months (mean)	13.4% per year in those with a consensus diagnosis of LGD

*Includes some of the important studies, not intended to include all studies published in the literature; f/u: followup; LGD: low-grade dysplasia; HGD: high-grade dysplasia; EAC: esophageal adenocarcinoma.